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A phase 1 dose-finding study of intravenous L-citrulline in
sickle cell disease: a potential novel therapy for sickle cell pain
crisis

Acute pain from vaso-occlusion (VOC) in sickle cell disease
(SCD) is the most frequent cause of emergency room visits
and hospital admissions, contributing to the high burden of
health care costs (Lanzkron et al, 2010). While major
advances in the care of patients with SCD have occurred over
the last 30 years, very little progress has been made in the
actual treatment of VOC.
Nitric oxide (NO) is a powerful vasodilator that plays a
fundamental role in VOC (Morris, 2008). NO is produced
from L-citrulline and L-arginine, amino acids generated
through the urea cycle from the NO synthase (NOS) family
of enzymes (Moncada & Higgs, 1993). There are three NOS
isoforms: neuronal (nNOS) found in neuronal tissue, inducible NOS (iNOS) found in cells and tissues, and endothelial
NOS (eNOS) found in vascular endothelial cells. Shen et al
(2005) showed that citrulline was the major supply for intracellular L-arginine and endothelial NO production in murine
endothelial cells. Furthermore, Wijnands et al (2012) showed
that L-citrulline supplementation restored intracellular NO
production, which was related to the degree of eNOS phosphorylation. Moreover, enhanced arginase-induced arginine
consumption is believed to play an integral role in the pathogenesis of sickle cell complications. In a more recent study,
L-citrulline supplementation increased NO production and
improved microcirculatory flow during conditions with arginase-induced arginine deficiency (Wijnands et al, 2015).
However, intravenous citrulline has never been evaluated in
human SCD. Hence, this study aimed to characterize the
pharmacokinetic (PK) and safety profile of intravenous (IV)
citrulline in this unique patient population.
A single centre open label phase 1 trial of IV citrulline was
performed in participants with SCD following approval from
the University of Mississippi Medical Center (UMMC) institutional review board. The study was registered at ClinicalTrials.gov (NCT02314689; NCT02697240), where the
inclusion and exclusion criteria are described. Th phase 1
study was performed in two steps. Step 1 included a dose
escalation bolus infusion of IV citrulline in steady-state SCD
to determine the PK and safety profile with a peak goal
plasma citrulline concentration of 80–100 lmol/l (Barr et al,
2007). Step 2 of the study was performed to evaluate safety
and PK during a vaso-occlusive crisis.
The study drug, L-citrulline, was administered as open
label vials of 50 mg/ml (5%) isotonic solution. Plasma

doi: 10.1111/bjh.15124

sampling for PK studies were collected at specific time
points. Briefly, for amino acid analysis, deproteinated plasma
samples were subjected to cation exchange chromatography
using a 4-component pH and ionic strength graded lithium
citrate buffer system on a Beckmann 7300 amino acid analyser (Beckmann, Palo Alto, CA). Data obtained for each
patient was fitted to a single-compartment PK model. The
appearance of citrulline in plasma was described by a zeroorder process (rate of citrulline appearance, Rapp) to account
for endogenous production, whereas the removal of citrulline
was determined by a first-order process (constant of citrulline removal, krem). It was assumed that the values of all
parameters remained constant for each patient during the
course of plasma sampling. Scientist v2.0 (Micromath Scientific Software, St. Louis, MO) was used to fit the plasma
citrulline concentration to the PK model by a weighted, least
squares procedure to obtain values for Rapp, krem, and the
volume of distribution (Vd). Clearance was calculated as the
product of krem and Vd.
For safety assessments, the Investigator determined the
intensity of any adverse event (AE) according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events Version 4.03 (https://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) and their
causal relationship. A Data Safety Monitoring Board, comprising 3 physicians who were not related to the study,
reviewed every third subject.
A total of 8 subjects with SCD were enrolled in this phase
1 study of IV citrulline: four participants were enrolled in
Step 1 and another four participants in Step 2. Patient demographics, genotype and baseline blood counts are shown in
Table SI. In the first cohort of four participants, the IV bolus
infusion of 20 mg/kg of L-citrulline yielded a mean peak
level of 259 lmol/l and trough level in the range of
20–40 lmol/l at 4 h after infusion (Fig 1). Citrulline PK
parameters for Step 1 with bolus infusion are shown in
Table SII. Pharmacokinetic model simulations indicated a
20 mg/kg bolus dose of IV citrulline followed by 7 mg/kg
per hour continuous infusion was needed to maintain the
target citrulline plasma concentration of 100 lmol/l. Subsequently, four subjects with VOC were enrolled to receive IV
citrulline bolus and continuous infusion. Individuals with
VOC showed significantly lower baseline citrulline levels
compared to steady-state (mean  SD: 937  143 vs.
ª 2018 British Society for Haematology and John Wiley & Sons Ltd
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Fig 1. Graphs showing plasma citrulline and
arginine levels over time after an intravenous
bolus infusion of 20 mg/kg L-citrulline.

Fig 2. Graphs showing plasma citrulline and
arginine levels over time after an intravenous
bolus of 20 mg/kg followed by a continuous
infusion of 7 mg/kg per hour L-citrulline.

2228  68, P = 001) (Figure S1). After the IV bolus, mean
peak plasma concentrations was 257 lmol/l and citrulline
plasma concentrations of approximately 100 lmol/l were
achieved during a 7 mg/kg per hour continuous infusion.
Furthermore, there was a robust and durable rise in both
citrulline and arginine levels (Fig 2). The citrulline PK
parameters for Step 2 with the bolus and IV continuous
infusion are shown in Table SIII. The endogenous citrulline
appearance rate (Rapp) was significantly lower in the VOC
cohort compared to steady-state (50 lmol/h/kg vs
111 lmol/h/kg, P = 0014).
Overall, intravenous citrulline in SCD was well tolerated
and safe. There were no AEs ≥ grade 2 level of toxicity.
Drowsiness was noted in 6 participants, but not severe
enough to discontinue study medication. One patient
reported feeling cold and one patient had nausea (no vomiting) associated with the drowsiness. Due to the theoretical
risk of vasodilation from the NO boost, vital signs were followed closely (Figure S2). In one subject, the diastolic blood
pressure transiently dropped >20% from baseline during the
first 30 min of drug administration but normalized within
1 h without any intervention. There were no significant
changes in the complete blood count and renal function tests
(Table SIV). However, one subject was readmitted about
2 weeks later with right upper quadrant painelevated alanine
transaminase and aspartate transaminase, peaking at 367 and
335 u/l respectively, which resolved by day 31. The subject
ª 2018 British Society for Haematology and John Wiley & Sons Ltd
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developed fever during hospitalization; tests revealed cytomegalovirus (CMV) IgM positivity and CMV polymerase chain
reaction of 6300 copies, suggesting acute CMV infection as
an aetiology. This was reported to the US Food and Drug
Administration as a serious AE.
This is the first report on the use of intravenous citrulline
in SCD. While this intervention was well tolerated, drowsiness was a potential side effect of unclear aetiology that
could be related to vasodilation of the cerebral vasculature
or, perhaps, improvement in pain. Given the potential benefit of boosting endothelial NO and contributing to microcirculatory vasodilation, studies are needed to evaluate the
efficacy of intravenous citrulline during a vaso-occlusive
crisis.
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